$ARQT
Arcutis Biotherapeutics Inc

2023 Q4 Form 10-Q Financial Statement

#000178730623000124 Filed on November 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $13.53M $38.11M $725.0K
YoY Change 356.81% 5156.41%
Cost Of Revenue $2.246M $1.180M $269.0K
YoY Change 363.09% 338.66%
Gross Profit $11.28M $36.93M $456.0K
YoY Change 355.57% 7998.68%
Gross Profit Margin 83.39% 96.91% 62.9%
Selling, General & Admin $48.67M $47.60M $35.47M
YoY Change 31.47% 34.17% 115.33%
% of Gross Profit 431.51% 128.88% 7779.17%
Research & Development $23.78M $26.24M $69.73M
YoY Change -29.82% -62.38% 71.73%
% of Gross Profit 210.77% 71.04% 15291.89%
Depreciation & Amortization $385.0K $200.0K $157.0K
YoY Change 10.95% 27.39% 35.34%
% of Gross Profit 3.41% 0.54% 34.43%
Operating Expenses $72.45M $75.01M $105.5M
YoY Change 2.18% -28.88% 84.79%
Operating Profit -$61.17M -$36.90M -$104.7M
YoY Change -10.6% -64.77% 83.52%
Interest Expense -$7.762M $7.559M $4.899M
YoY Change 12.25% 54.3%
% of Operating Profit
Other Income/Expense, Net $2.672M $2.721M -$2.961M
YoY Change -19.52% -191.89% -3121.43%
Pretax Income -$66.26M -$41.74M -$107.7M
YoY Change -8.0% -61.25% 89.03%
Income Tax $25.00K $3.000M $0.00
% Of Pretax Income
Net Earnings -$66.28M -$44.77M -$107.7M
YoY Change -7.96% -58.44% 89.03%
Net Earnings / Revenue -490.05% -117.47% -14856.41%
Basic Earnings Per Share -$0.73 -$1.89
Diluted Earnings Per Share -$0.71 -$0.73 -$1.89
COMMON SHARES
Basic Shares Outstanding 94.38M shares 61.65M shares 51.56M shares
Diluted Shares Outstanding 61.73M shares 57.09M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.9M $227.1M $477.0M
YoY Change -33.63% -52.38% 29.87%
Cash & Equivalents $88.40M $107.5M $81.54M
Short-Term Investments $183.5M $119.6M $395.4M
Other Short-Term Assets $19.63M $21.10M $13.02M
YoY Change 65.72% 62.08% -7.92%
Inventory $13.13M $13.91M $4.307M
Prepaid Expenses
Receivables $25.81M $19.42M $2.431M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $330.4M $281.5M $496.7M
YoY Change -24.46% -43.32% 30.11%
LONG-TERM ASSETS
Property, Plant & Equipment $1.539M $1.735M $1.939M
YoY Change -18.18% -10.52% -5.18%
Goodwill
YoY Change
Intangibles $6.438M $6.625M $7.375M
YoY Change -10.43% -10.17%
Long-Term Investments
YoY Change
Other Assets $596.0K $596.0K $78.00K
YoY Change 664.1% 664.1% 0.0%
Total Long-Term Assets $10.93M $11.41M $12.20M
YoY Change -7.87% -6.43% 132.82%
TOTAL ASSETS
Total Short-Term Assets $330.4M $281.5M $496.7M
Total Long-Term Assets $10.93M $11.41M $12.20M
Total Assets $341.4M $293.0M $508.9M
YoY Change -24.02% -42.43% 31.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.99M $13.18M $8.666M
YoY Change 35.86% 52.08% 77.91%
Accrued Expenses $33.94M $28.00M $27.80M
YoY Change 19.84% 0.71% 100.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $46.67M $41.89M $37.10M
YoY Change 23.44% 12.9% 94.68%
LONG-TERM LIABILITIES
Long-Term Debt $201.8M $200.8M $196.8M
YoY Change 2.04% 2.05%
Other Long-Term Liabilities $849.0K $3.600M $0.00
YoY Change -100.0%
Total Long-Term Liabilities $202.6M $200.8M $196.8M
YoY Change 2.47% 2.05% 634587.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.67M $41.89M $37.10M
Total Long-Term Liabilities $202.6M $200.8M $196.8M
Total Liabilities $252.7M $246.2M $238.1M
YoY Change 5.43% 3.4% 891.71%
SHAREHOLDERS EQUITY
Retained Earnings -$981.9M -$915.6M -$647.7M
YoY Change 36.41% 41.36% 92.2%
Common Stock $9.000K $6.000K $6.000K
YoY Change 50.0% 0.0% 20.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.67M $46.72M $270.8M
YoY Change
Total Liabilities & Shareholders Equity $341.4M $293.0M $508.9M
YoY Change -24.02% -42.43% 31.5%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$66.28M -$44.77M -$107.7M
YoY Change -7.96% -58.44% 89.03%
Depreciation, Depletion And Amortization $385.0K $200.0K $157.0K
YoY Change 10.95% 27.39% 35.34%
Cash From Operating Activities -$56.24M -$43.98M -$67.70M
YoY Change -20.86% -35.03% 65.58%
INVESTING ACTIVITIES
Capital Expenditures $6.000K $60.00K -$22.96M
YoY Change -95.12% -100.26% 16656.2%
Acquisitions
YoY Change
Other Investing Activities -$62.18M $45.61M -$174.3M
YoY Change -246.91% -126.17% -4931.1%
Cash From Investing Activities -$62.19M $45.55M -$197.3M
YoY Change -247.36% -123.09% -5783.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.29M 860.0K 285.0M
YoY Change 10221.1% -99.7% 452263.49%
NET CHANGE
Cash From Operating Activities -56.24M -43.98M -67.70M
Cash From Investing Activities -62.19M 45.55M -197.3M
Cash From Financing Activities 99.29M 860.0K 285.0M
Net Change In Cash -19.14M 2.430M 20.03M
YoY Change -31.4% -87.87% -153.63%
FREE CASH FLOW
Cash From Operating Activities -$56.24M -$43.98M -$67.70M
Capital Expenditures $6.000K $60.00K -$22.96M
Free Cash Flow -$56.25M -$44.04M -$44.74M
YoY Change -20.98% -1.56% 9.8%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107471000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53641000 usd
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61037403 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
962515000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
930425000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-184000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1086000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915620000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-719764000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
46717000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
209581000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292959000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
449274000 usd
CY2023Q3 arqt Cost Of Sales
CostOfSales
1182000 usd
CY2022Q3 arqt Cost Of Sales
CostOfSales
269000 usd
arqt Cost Of Sales
CostOfSales
2741000 usd
arqt Cost Of Sales
CostOfSales
269000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26236000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
69731000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47595000 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
35473000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
75013000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
105473000 usd
us-gaap Operating Expenses
OperatingExpenses
226012000 usd
us-gaap Operating Expenses
OperatingExpenses
233928000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-36904000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-104748000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2721000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1938000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
7559000 usd
us-gaap Interest Expense
InterestExpense
21950000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
246242000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
239693000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61861736 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61052250 shares
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
38109000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
725000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
46080000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
725000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
4899000 usd
us-gaap Interest Expense
InterestExpense
8737000 usd
CY2023Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-41742000 usd
CY2022Q3 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-107709000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3023000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-44765000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-107709000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108053000 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.73
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.19
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.19
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
61727278 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
61727278 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
297677000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
260000 usd
CY2022Q1 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
25000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6533000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-765000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-64324000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
253772000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
156000 usd
CY2022Q2 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
20000 usd
CY2022Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
10844000 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161657000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
12468000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
494000 usd
CY2022Q3 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
37000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8789000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-344000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
209581000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
100000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0 usd
CY2023Q1 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9479000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
724000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-52000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-80100000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
139732000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
74000 usd
CY2023Q2 arqt Stock Issued During Period Vesting Of Founder Value Subject To Repurchase Shares
StockIssuedDuringPeriodVestingOfFounderValueSubjectToRepurchaseShares
0 usd
CY2023Q2 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
0 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
993000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10578000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
128000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-70991000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
80508000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
867000 usd
CY2023Q3 arqt Stock Issued During Period Lapse Of Repurchase Rights Pursuant To Early Stock Exercises
StockIssuedDuringPeriodLapseOfRepurchaseRightsPursuantToEarlyStockExercises
0 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9999000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
165000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-57000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
46717000 usd
us-gaap Net Income Loss
NetIncomeLoss
-195856000 usd
us-gaap Net Income Loss
NetIncomeLoss
-239439000 usd
us-gaap Depreciation
Depreciation
573000 usd
us-gaap Depreciation
Depreciation
462000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
266000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
237000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
563000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125000 usd
arqt Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
arqt Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
29630000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5517000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-89000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
3014000 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1590000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
30056000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
23418000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10959000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2431000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6399000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4307000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10087000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2299000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4345000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1383000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-323000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
577000 usd
arqt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-489000 usd
arqt Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-283000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-190813000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-186650000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
107660000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
377301000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
350500000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
271061000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
422000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
210000 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
0 usd
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
15450000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
7500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
242418000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-129400000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1041000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000000 usd
arqt Proceeds From Issuance Of Shares Under At The Market Offering Net Of Issuance Costs
ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts
0 usd
arqt Proceeds From Issuance Of Shares Under At The Market Offering Net Of Issuance Costs
ProceedsFromIssuanceOfSharesUnderAtTheMarketOfferingNetOfIssuanceCosts
14455000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
161592000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
993000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
976000 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 usd
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
125000000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2187000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2034000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
300836000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-118000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53521000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15214000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54875000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
97991000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108396000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82777000 usd
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
18862000 usd
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
6923000 usd
arqt Acquired In Process Research And Development Obtained In Exchange For Issuance Of Common Stock
AcquiredInProcessResearchAndDevelopmentObtainedInExchangeForIssuanceOfCommonStock
0 usd
arqt Acquired In Process Research And Development Obtained In Exchange For Issuance Of Common Stock
AcquiredInProcessResearchAndDevelopmentObtainedInExchangeForIssuanceOfCommonStock
12468000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-915600000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-719800000 usd
CY2023Q3 arqt Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
228000000 usd
CY2022Q4 arqt Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
410800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, management evaluates such estimates and assumptions for continued reasonableness. In particular, management makes estimates with respect to revenue recognition, accruals for research and development activities, stock-based compensation expense, and income taxes. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Actual results could differ from those estimates.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
900000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
1200000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q3 arqt Intangible Assets Milestone Payment
IntangibleAssetsMilestonePayment
7500000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
188000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
563000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
125000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
188000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
750000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
750000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
750000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
750000 usd
CY2023Q3 arqt Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
3438000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
6626000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
Concentration of Credit Risk and Other Risks and Uncertainties<span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company is exposed to credit risk in the event of a default by either the financial institutions holding its cash or by its customers owing trade receivables to the extent recorded on the condensed consolidated</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span>balance sheets. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses.
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2022Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
CY2023Q3 us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
0 usd
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3100000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3034000 usd
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1726000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1153000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1735000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1881000 usd
CY2023Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
227113000 usd
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
409589000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
107471000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
107471000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
119711000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
5000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
74000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
119642000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53641000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
53641000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
357034000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1093000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
355948000 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q3 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P18M
CY2023Q3 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P18M
CY2023Q3 arqt Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
4948000 usd
CY2022Q4 arqt Prepaid Copay Assistance Program
PrepaidCopayAssistanceProgram
3226000 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13741000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14000000 usd
CY2023Q3 arqt Accrued Sales Deductions Current
AccruedSalesDeductionsCurrent
7308000 usd
CY2022Q4 arqt Accrued Sales Deductions Current
AccruedSalesDeductionsCurrent
1567000 usd
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3461000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
200000 usd
us-gaap Depreciation
Depreciation
573000 usd
CY2022Q3 us-gaap Depreciation
Depreciation
157000 usd
us-gaap Depreciation
Depreciation
462000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
241000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
995000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1024000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1054000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1087000 usd
CY2023Q3 arqt Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
653000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5054000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
769000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4285000 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
715000 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3570000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
4285000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
184000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
551000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
186000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
530000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
723000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
547000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y9M18D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.070
CY2023Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
1200000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
800000 usd
CY2023Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
800000 usd
CY2023Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000 usd
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
200000000 usd
CY2023Q3 arqt Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
4118000 usd
CY2022Q4 arqt Debt Instrument Accrued Final Fee
DebtInstrumentAccruedFinalFee
1871000 usd
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3335000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4102000 usd
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
200783000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
197769000 usd
CY2023Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
213900000 usd
CY2023Q3 arqt Common Stock Voting Rights Number Of Votes Per Share
CommonStockVotingRightsNumberOfVotesPerShare
1 vote
CY2023Q3 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
0 usd
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15080264 shares
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12837138 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2020Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7476223 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.93
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M23D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
18667000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1608110 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.67
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
239517 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
479288 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
20.48
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
137258 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
26.75
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8228270 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M3D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3269000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4571413 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M2D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3269000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1200000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
22100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.76
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9999000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8789000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
30056000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
23418000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11229576 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9122294 shares
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001787306-23-000124-index-headers.html Edgar Link pending
0001787306-23-000124-index.html Edgar Link pending
0001787306-23-000124.txt Edgar Link pending
0001787306-23-000124-xbrl.zip Edgar Link pending
arqt-20230930.htm Edgar Link pending
arqt-20230930.xsd Edgar Link pending
exhibit311ceoq32023.htm Edgar Link pending
exhibit312cfoq32023.htm Edgar Link pending
exhibit321ceocfoq32023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
huadonglicenseandcollabo.htm Edgar Link pending
huadonglicenseandcollabo001.jpg Edgar Link pending
huadonglicenseandcollabo002.jpg Edgar Link pending
huadonglicenseandcollabo003.jpg Edgar Link pending
huadonglicenseandcollabo004.jpg Edgar Link pending
huadonglicenseandcollabo005.jpg Edgar Link pending
huadonglicenseandcollabo006.jpg Edgar Link pending
huadonglicenseandcollabo007.jpg Edgar Link pending
huadonglicenseandcollabo008.jpg Edgar Link pending
huadonglicenseandcollabo009.jpg Edgar Link pending
huadonglicenseandcollabo010.jpg Edgar Link pending
huadonglicenseandcollabo011.jpg Edgar Link pending
huadonglicenseandcollabo012.jpg Edgar Link pending
huadonglicenseandcollabo013.jpg Edgar Link pending
huadonglicenseandcollabo014.jpg Edgar Link pending
huadonglicenseandcollabo015.jpg Edgar Link pending
huadonglicenseandcollabo016.jpg Edgar Link pending
arqt-20230930_cal.xml Edgar Link unprocessable
arqt-20230930_def.xml Edgar Link unprocessable
arqt-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
arqt-20230930_htm.xml Edgar Link completed
huadonglicenseandcollabo017.jpg Edgar Link pending
huadonglicenseandcollabo018.jpg Edgar Link pending
huadonglicenseandcollabo019.jpg Edgar Link pending
huadonglicenseandcollabo020.jpg Edgar Link pending
huadonglicenseandcollabo021.jpg Edgar Link pending
huadonglicenseandcollabo022.jpg Edgar Link pending
huadonglicenseandcollabo023.jpg Edgar Link pending
huadonglicenseandcollabo024.jpg Edgar Link pending
huadonglicenseandcollabo025.jpg Edgar Link pending
huadonglicenseandcollabo026.jpg Edgar Link pending
huadonglicenseandcollabo027.jpg Edgar Link pending
huadonglicenseandcollabo028.jpg Edgar Link pending
huadonglicenseandcollabo029.jpg Edgar Link pending
huadonglicenseandcollabo030.jpg Edgar Link pending
huadonglicenseandcollabo031.jpg Edgar Link pending
huadonglicenseandcollabo032.jpg Edgar Link pending
huadonglicenseandcollabo033.jpg Edgar Link pending
huadonglicenseandcollabo034.jpg Edgar Link pending
huadonglicenseandcollabo035.jpg Edgar Link pending
huadonglicenseandcollabo036.jpg Edgar Link pending
huadonglicenseandcollabo037.jpg Edgar Link pending
huadonglicenseandcollabo038.jpg Edgar Link pending
huadonglicenseandcollabo039.jpg Edgar Link pending
huadonglicenseandcollabo040.jpg Edgar Link pending
huadonglicenseandcollabo041.jpg Edgar Link pending
huadonglicenseandcollabo042.jpg Edgar Link pending
huadonglicenseandcollabo043.jpg Edgar Link pending
huadonglicenseandcollabo044.jpg Edgar Link pending
huadonglicenseandcollabo045.jpg Edgar Link pending
huadonglicenseandcollabo046.jpg Edgar Link pending
huadonglicenseandcollabo047.jpg Edgar Link pending
huadonglicenseandcollabo048.jpg Edgar Link pending
huadonglicenseandcollabo049.jpg Edgar Link pending
huadonglicenseandcollabo050.jpg Edgar Link pending
huadonglicenseandcollabo051.jpg Edgar Link pending
huadonglicenseandcollabo052.jpg Edgar Link pending
huadonglicenseandcollabo053.jpg Edgar Link pending
huadonglicenseandcollabo054.jpg Edgar Link pending
huadonglicenseandcollabo055.jpg Edgar Link pending
huadonglicenseandcollabo056.jpg Edgar Link pending
huadonglicenseandcollabo057.jpg Edgar Link pending
huadonglicenseandcollabo058.jpg Edgar Link pending
huadonglicenseandcollabo059.jpg Edgar Link pending
huadonglicenseandcollabo060.jpg Edgar Link pending
huadonglicenseandcollabo061.jpg Edgar Link pending
huadonglicenseandcollabo062.jpg Edgar Link pending
huadonglicenseandcollabo063.jpg Edgar Link pending
huadonglicenseandcollabo064.jpg Edgar Link pending
huadonglicenseandcollabo065.jpg Edgar Link pending
huadonglicenseandcollabo066.jpg Edgar Link pending
huadonglicenseandcollabo067.jpg Edgar Link pending
huadonglicenseandcollabo068.jpg Edgar Link pending
huadonglicenseandcollabo069.jpg Edgar Link pending
huadonglicenseandcollabo070.jpg Edgar Link pending
huadonglicenseandcollabo071.jpg Edgar Link pending
huadonglicenseandcollabo072.jpg Edgar Link pending
huadonglicenseandcollabo073.jpg Edgar Link pending
huadonglicenseandcollabo074.jpg Edgar Link pending
huadonglicenseandcollabo075.jpg Edgar Link pending
huadonglicenseandcollabo076.jpg Edgar Link pending
huadonglicenseandcollabo077.jpg Edgar Link pending
huadonglicenseandcollabo078.jpg Edgar Link pending
huadonglicenseandcollabo079.jpg Edgar Link pending
huadonglicenseandcollabo080.jpg Edgar Link pending
huadonglicenseandcollabo081.jpg Edgar Link pending
huadonglicenseandcollabo082.jpg Edgar Link pending
huadonglicenseandcollabo083.jpg Edgar Link pending
huadonglicenseandcollabo084.jpg Edgar Link pending
huadonglicenseandcollabo085.jpg Edgar Link pending
huadonglicenseandcollabo086.jpg Edgar Link pending
huadonglicenseandcollabo087.jpg Edgar Link pending
huadonglicenseandcollabo088.jpg Edgar Link pending
huadonglicenseandcollabo089.jpg Edgar Link pending
huadonglicenseandcollabo090.jpg Edgar Link pending
huadonglicenseandcollabo091.jpg Edgar Link pending
huadonglicenseandcollabo092.jpg Edgar Link pending
huadonglicenseandcollabo093.jpg Edgar Link pending
huadonglicenseandcollabo094.jpg Edgar Link pending
huadonglicenseandcollabo095.jpg Edgar Link pending
huadonglicenseandcollabo096.jpg Edgar Link pending
huadonglicenseandcollabo097.jpg Edgar Link pending
huadonglicenseandcollabo098.jpg Edgar Link pending
huadonglicenseandcollabo099.jpg Edgar Link pending
huadonglicenseandcollabo100.jpg Edgar Link pending
huadonglicenseandcollabo101.jpg Edgar Link pending
huadonglicenseandcollabo102.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
slrfirstamendmenttoarloa.htm Edgar Link pending
slrfirstamendmenttoarloa001.jpg Edgar Link pending
slrfirstamendmenttoarloa002.jpg Edgar Link pending
slrfirstamendmenttoarloa003.jpg Edgar Link pending
slrfirstamendmenttoarloa004.jpg Edgar Link pending
slrfirstamendmenttoarloa005.jpg Edgar Link pending
slrfirstamendmenttoarloa006.jpg Edgar Link pending
slrfirstamendmenttoarloa007.jpg Edgar Link pending
slrfirstamendmenttoarloa008.jpg Edgar Link pending
slrfirstamendmenttoarloa009.jpg Edgar Link pending
slrfirstamendmenttoarloa010.jpg Edgar Link pending
arqt-20230930_lab.xml Edgar Link unprocessable